U.S. Markets closed

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
11.82+0.22 (+1.90%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    BrianX
    Stock being jerked around a lot lately for whatever reasons. In quick summary, given about 1 billion in sales a year and the shares outstanding, the wound care part of Mimedx would sell for about $9-10/share. Given that no company trades at that value but near 70% of it, that puts where the stock price would be with wound care alone at $7-8/share. So at the current price of around $11, the market is valuing the potential injectable products/ overseas sales etc at about $3/share. This leads to the conclusion that either we are delusional expecting $30/share down the road or the market has no clue about what is about to happen. Why has all the show and tell done over the past year and the approaching clinical results not yielded a better response/stock price? IMO it has nothing to do with manipulation/shorts etc., its just the past history of financial chicanery has led to a severe lack of trust even with the new management team. I am long because I believe that is about to change.
  • p
    patrick
    https://utradea.com/positions/MiMedx__Management_Miscommunication_Skews_Valuation_Down_and_Creates_Great_Buying_Opportunity
  • m
    misrespet
    Good, the target now raised to $17+ and some analysts have raised their target to $20...likely to bump $30s next year.
  • B
    Beef
    @BrianX - Brian, drop her like the bad habit that she is. Really - just block her so the lies, the taunts, the childishness, the immature cartoons and irrelevant pictures - they all just disappeart. She a small time #$%$ Period. Nothing more.
  • B
    Beef
    MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare (JMHLW) to market EPIFIX® in Japan.
  • m
    misrespet
    Good, another milestone met at $12.00, no big deal because I see $14 to $18 as the current value.
    Yes, I'm in long and holding not day trading this stock. I agree with the $30+ target not far down the pike.
  • B
    Bill
    Well was there any information provided at the Raymond James fish fry?
  • G
    Gynot
    Tim Wright hold 1.3mm shares of MiMedx I think he's focused on success....His sale "Reflects sale of shares to cover tax withholding obligation upon vesting of previously-granted award."
  • B
    Beef
    Every time these AH market makers drop the price like this morning I am a buyer...these AHs wouldn't know a "fair and orderly market" if it landed in their lap ...so I take advantage. Thanks clowns!
  • C
    Charly
    https://www.globenewswire.com/news-release/2021/06/15/2247782/0/en/New-Study-Demonstrates-Potential-for-MIMEDX-Purion-Processed-Dehydrated-Human-Amnion-Chorion-Membrane-to-Modulate-Pathological-Scar-Tissue-Formation.html
    Bullish
  • C
    Charly
    SP manipulation by Wall Street Boys 🤑
  • B
    Beef
    MDXG reached 50% of its average daily volume by 11am today
  • p
    paul
    Volume and price seems are steadily rising. Are we getting close to a news release on trial data? Hope so!
  • C
    Charly
    https://www.globenewswire.com/news-release/2021/06/16/2248141/0/en/MIMEDX-to-Present-at-the-Raymond-James-2021-Human-Health-Innovation-Conference.html
    Bullish
  • m
    misrespet
    With litigation and covid seeing an end MDXG should see an uptick in sales. The debt paydown from $65.7 to $47.7m of near $18m is about $.16 per share and perhaps $.02 savings in interest. I am looking for much better earnings next quarter and so a higher price. $14 to $18 is in my sights for next quarter.
  • B
    Beef
    MDXG added to the Russell 3000
  • D
    Darla
    Do you think there is a buyout in the near future?? I know it was talked about a few months ago...
  • m
    misrespet
    Day traders bouncing off the chart but they can't stop MDXG going up. The institutional buyers rule here with all the good news.
  • m
    misrespet
    Epifix in Japan...I had that roughly figured based on population.. I am very busy today but will try to find my notes on that or figure it again.
  • C
    Charly
    Next target $15
    Bullish